{"id":411899,"date":"2021-01-11T08:03:28","date_gmt":"2021-01-11T13:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411899"},"modified":"2021-01-11T08:03:28","modified_gmt":"2021-01-11T13:03:28","slug":"pharmabcine-announces-a-research-collaboration-with-legochem-biosciences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/","title":{"rendered":"PharmAbcine announces a research collaboration with LegoChem Biosciences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>DAEJEON, <span class=\"xn-location\">South Korea<\/span>, <span class=\"xn-chron\">Jan. 11, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics,\u00a0announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks), a biopharmaceutical company focusing on the research and development of ADCs (Antibody-Drug Conjugates) in <span class=\"xn-location\">South Korea<\/span>. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3210\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg\" title=\"PharmAbcineLogo (PRNewsfoto\/PharmAbcine)\" alt=\"PharmAbcineLogo (PRNewsfoto\/PharmAbcine)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Under the agreement, PharmAbcine will provide PMC-403, a preclinical pipeline, to LCB so LCB can conduct a combination research using PMC-403 and LCB&#8217;s proprietary ADC. This preclinical study will allow both parties to evaluate the efficacy of the combination therapy in solid tumors.<\/p>\n<p>Dr. Yong Zu Kim. CEO &amp; President of LegoChem said &#8220;Currently, our company is widening the development areas such as monoclone antibody-ADC, which is being mainly developed, as well as bispecific antibody-ADC and combination therapy with various drugs. With this agreement, we will try to secure an additional high value-added pipeline by confirming the possibility of combination therapy with our ADC candidates and PharmAbcine&#8217;s drug&#8221;<\/p>\n<p>&#8220;We are excited about this agreement with LegoChem Biosciences, a global leader in ADC. We have been emphasizing wide application of PMC-403 to potential partners and investors in recent months,&#8221; said Dr. <span class=\"xn-person\">Jin-San Yoo<\/span>, CEO of PharmAbcine. &#8220;This agreement marks an important milestone in exploring the full potential of PMC-403.&#8221;<\/p>\n<p>PMC-403, a Tie2-activating antibody, is a next generation therapeutic antibody that regulates the formation of functional blood vessels.\u00a0 It is expected to induce normalization of leaky blood vessels formed around tumor mass in a ligand-independent manner. It has demonstrated its anti-tumor effect in a mouse model for colon cancer, corroborated by the improvement in immune cell infiltration and delivery of anti-cancer agents to a tumor site when administered as a single agent or as a combination therapy regimen. <\/p>\n<p>PMC-403 also stabilizes and repairs damaged blood vessels in non-oncology indications. PharmAbcine is currently developing PMC-403 for ophthalmology indications such as AMD (Age-related Macular Degeneration).<\/p>\n<p>About LegoChem Biosciences Inc.<\/p>\n<p>LegoChem Biosciences is a biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary medicinal drug discovery technology LegoChemistry\u2122 &amp; ADC platform technology ConjuAll\u2122.\u00a0 Since its foundation in 2006, LCB has focused on the research and development of ADC (Antibody-Drug-Conjugates), antibiotics, anticoagulants and anticancer therapeutics based on proprietary platform technologies.<\/p>\n<p>About PharmAbcine Inc.<\/p>\n<p>PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, to respiratory.<\/p>\n<p>PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine&#8217;s advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state of the art antibody generation services.<\/p>\n<p>For additional information about PharmAbcine, visit <a target=\"_blank\" href=\"http:\/\/www.pharmabcine.com\/\" rel=\"nofollow noopener noreferrer\">http:\/\/www.pharmabcine.com<\/a>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN39817&amp;sd=2021-01-11\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences-301203257.html\">http:\/\/www.prnewswire.com\/news-releases\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences-301203257.html<\/a><\/p>\n<p>SOURCE  PharmAbcine<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN39817&amp;Transmission_Id=202101110800PR_NEWS_USPR_____CN39817&amp;DateId=20210111\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire DAEJEON, South Korea, Jan. 11, 2021 \/PRNewswire\/ &#8212;\u00a0PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics,\u00a0announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks), a biopharmaceutical company focusing on the research and development of ADCs (Antibody-Drug Conjugates) in South Korea. Under the agreement, PharmAbcine will provide PMC-403, a preclinical pipeline, to LCB so LCB can conduct a combination research using PMC-403 and LCB&#8217;s proprietary ADC. This preclinical study will allow both parties to evaluate the efficacy of the combination therapy in solid tumors. Dr. Yong Zu Kim. CEO &amp; President of LegoChem said &#8220;Currently, our company is widening the development areas &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;PharmAbcine announces a research collaboration with LegoChem Biosciences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411899","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DAEJEON, South Korea, Jan. 11, 2021 \/PRNewswire\/ &#8212;\u00a0PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics,\u00a0announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks), a biopharmaceutical company focusing on the research and development of ADCs (Antibody-Drug Conjugates) in South Korea. Under the agreement, PharmAbcine will provide PMC-403, a preclinical pipeline, to LCB so LCB can conduct a combination research using PMC-403 and LCB&#8217;s proprietary ADC. This preclinical study will allow both parties to evaluate the efficacy of the combination therapy in solid tumors. Dr. Yong Zu Kim. CEO &amp; President of LegoChem said &#8220;Currently, our company is widening the development areas &hellip; Continue reading &quot;PharmAbcine announces a research collaboration with LegoChem Biosciences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T13:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"PharmAbcine announces a research collaboration with LegoChem Biosciences\",\"datePublished\":\"2021-01-11T13:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/\"},\"wordCount\":492,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/\",\"name\":\"PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"datePublished\":\"2021-01-11T13:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1176198\\\/PharmAbcineLogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PharmAbcine announces a research collaboration with LegoChem Biosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/","og_locale":"en_US","og_type":"article","og_title":"PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk","og_description":"PR Newswire DAEJEON, South Korea, Jan. 11, 2021 \/PRNewswire\/ &#8212;\u00a0PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics,\u00a0announced today that the company has entered into a research collaboration agreement with LegoChem Biosciences Inc. (KOSDAQ: 141080ks), a biopharmaceutical company focusing on the research and development of ADCs (Antibody-Drug Conjugates) in South Korea. Under the agreement, PharmAbcine will provide PMC-403, a preclinical pipeline, to LCB so LCB can conduct a combination research using PMC-403 and LCB&#8217;s proprietary ADC. This preclinical study will allow both parties to evaluate the efficacy of the combination therapy in solid tumors. Dr. Yong Zu Kim. CEO &amp; President of LegoChem said &#8220;Currently, our company is widening the development areas &hellip; Continue reading \"PharmAbcine announces a research collaboration with LegoChem Biosciences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T13:03:28+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"PharmAbcine announces a research collaboration with LegoChem Biosciences","datePublished":"2021-01-11T13:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/"},"wordCount":492,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/","name":"PharmAbcine announces a research collaboration with LegoChem Biosciences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","datePublished":"2021-01-11T13:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1176198\/PharmAbcineLogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharmabcine-announces-a-research-collaboration-with-legochem-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"PharmAbcine announces a research collaboration with LegoChem Biosciences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411899"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411899\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}